Frost D B, Patt Y Z, Mavligit G, Chuang V P, Wallace S
Arch Surg. 1985 Apr;120(4):478-80. doi: 10.1001/archsurg.1985.01390280068015.
We treated nine patients who had metastatic malignant melanoma confined to one extremity (8/9) or the vulva (1/9) with arterial dacarbazine and cisplatin at respective doses of 800 and 90 mg/sq m. We percutaneously introduced catheters into the extremity or regional artery under fluoroscopy by the Seldinger technique, removed them at the end of the infusions, and repositioned them at four-week intervals for repeated treatment cycles. One patient achieved a complete remission, three patients had partial remissions, and five patients' disease was stable. The group median survival will exceed 19 months. Three patients with stable disease died 6, 18, and 19 months after treatment initiation, respectively. The toxic effects were primarily nausea and vomiting, pain in the infused extremity, and local erythema. Arterial dacarbazine and cisplatin offer a more effective and less toxic alternative to higher-dose single-agent arterial cisplatin for locally advanced malignant melanoma.
我们对9例转移性恶性黑色素瘤局限于一个肢体（8/9）或外阴（1/9）的患者，分别以800和90mg/平方米的剂量给予动脉注射达卡巴嗪和顺铂进行治疗。我们通过Seldinger技术在透视引导下经皮将导管插入肢体或区域动脉，输液结束时取出导管，并每隔四周重新放置以进行重复治疗周期。1例患者达到完全缓解，3例患者部分缓解，5例患者病情稳定。该组中位生存期将超过19个月。3例病情稳定的患者分别在开始治疗后6、18和19个月死亡。毒性作用主要为恶心、呕吐、输注肢体疼痛和局部红斑。对于局部晚期恶性黑色素瘤，动脉注射达卡巴嗪和顺铂相对于高剂量单药动脉注射顺铂提供了一种更有效且毒性更小的替代方案。
